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Tenovin-6 (Tnv-6) is a bioactive small molecule with anti-neoplastic activity. Inhibition of the Sirtuin class
of protein deacetylases with activation of p53 function is associated with the pro-apoptotic effects of Tnv-6
in many tumors. Here, we demonstrate that in chronic lymphocytic leukemia (CLL) cells, Tnv-6 causes
non-genotoxic cytotoxicity, without adversely affecting human clonogenic hematopoietic progenitors in
vitro, or murine hematopoiesis. Mechanistically, exposure of CLL cells to Tnv-6 did not induce cellular
apoptosis or p53-pathway activity. Transcriptomic profiling identified a gene program influenced by Tnv-6
that included autophagy-lysosomal pathway genes. The dysregulation of autophagy was confirmed by
changes in cellular ultrastructure and increases in the autophagy-regulatory proteins LC3 (LC3-II) and p62/
Sequestosome. Adding bafilomycin-A1, an autophagy inhibitor to Tnv-6 containing cultures did not cause
synergistic accumulation of LC3-II, suggesting inhibition of late-stage autophagy by Tnv-6. Thus, in CLL,
the cytotoxic effects of Tnv-6 result from dysregulation of protective autophagy pathways.
C
hemotherapeutic drugs currently used to treat patients with chronic lymphocytic leukemia (CLL) achieve
disease control through genotoxic activation of p53-dependent signaling in leukemic cells1–3. The import-
ance of p53-pathway activity to clinical responses in CLL patients receiving chemotherapy has been
demonstrated both in vitro and in vivo1–7. Outcomes have improved further with the use of immunochemother-
apy8, but treatment-associated hematological toxicity is a significant problem, particularly in the elderly.
Resistance to therapy too can be a problem in patients with TP53 mutations5–7 or dysfunctional p53-associated
signal transduction4, and in disease progressing after previous nucleoside analogue exposure7. Consequently,
there is a need to develop non-toxic anti-leukemic agents capable of dysregulating leukemic cell survival through
novel mechanisms.
Newer therapeutic strategies against CLL include drugs that do not directly target the cellular genome. There
has been interest in the epigenetic targeting of CLL through inhibition of histone deacetylase (HDAC) enzymes9,
known to regulate chromatin remodeling and gene expression10–12. Most studies have investigated drugs that
inhibit class I, II and IVHDACenzymes10,13,14, and the effects of class IIIHDAC inhibition have only recently been
described15,16. Class III HDACs, also termed Sirtuins (SirT), are structurally distinct from class I and II HDACs,
and are evolutionary conserved NAD(1)-dependent acetyl-lysine deacetylases and ADP ribosyltransferases
involved in the tissue-specific control of cellular metabolism and lifespan17,18. The ability to prolong lifespan is
mediated through stimulation of autophagy, a highly conserved protective process that maintains cellular home-
ostasis during periods of stress19,20. In addition, Sirtuins can regulate cellular proliferation and survival through
the deacetylation of a variety of non-histone substrates that regulate cellular development21,22. Most notably,
Sirtuins act to deacetylate p53, thereby limiting p53-dependent growth arrest and apoptosis, making targeted
inhibition of these enzymes potentially therapeutic in neoplasia with wild-type TP53.
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Consistent with this view, compounds collectively referred to as
Tenovins23, were identified by a small molecule screen for agents that
induce p53 activation in tumor cells and were shown to target SirT1
and SirT2 (two of 7 Sirtuin isoforms). Tenovins induce apoptosis in
malignant cell lines, including those derived from lympho-reticular
neoplasia and decrease human tumor growth in xenograft models24,25.
In these studies, cell death was associated with inhibition of SirT-
induced p53 deacetylation and inactivation, resulting in amplification
of p53-dependent responses. Anti-leukaemic properties of Sirtuin
inhibitors have also been demonstrated in recent pre-clinical studies
on Tenovin in chronic myeloid leukaemia26,27 and Nicotinamide in
CLL15, in association with increased p53-pathway function. However,
Sirtuin antagonists differ in their specificity, binding-properties and
relative potencies against target enzymes28, and therefore, the bio-
logical effects of different Sirtuin inhibitors can be unique and tis-
sue-specific. Indeed, cell death in response to treatment with the
Sirtuin inhibitors sirtinol, cambinol or EX527 in CLL is associated
with p53-independent apoptosis16 and Tenovin can be cytotoxic even
in the presence of mutant TP5324.
Due to this potential for tissue and context-dependent differences
in biological responses achieved with Sirtuin inhibitors, we examined
the in vitro effects of one of the Tenovins, Tenovin-6 (Tnv-6) on
primary human CLL cells.
Results
SirT1 is expressed in CLL. Since Tenovins target Sirtuins and can
enhance wild-type p53 activity23–25, we first investigated whether CLL
cells express Sirtuins and contain wild-type p53. By Western
blotting, SirT1 protein was detectable at approximately 80 kDa in
protein extracts from all 10 CLL specimens screened. In some
specimens, additional bands were observed, particularly when the
exposure-time of the Western Blot was increased (Supplementary
Figure 1). However, despite longer exposure times, no band
indicative of SirT1 was detectable in normal blood lymphocytes.
Our observations thus confirm recent studies on SirT1 expression
in CLL15,34,35, and indicate heterogeneity of protein expression
between patients.
Sequencing of exons 5–9 of TP53 revealed no mutations and there
was absence of del(17p) by fluorescence in situ hybridization.
Anti-leukaemic cytotoxicity of Tnv-6 is similar to conventional
treatment. After 24 hours of culture, a dose-dependent cytotoxic
effect of Tnv-6 was evident in the MTS assay. The mean metabolic
activity from 10 patients (assayed in triplicate) with 10 mM of Tnv-6
(39.76 24.11%) was lower than with 5 mMor 1 mM (71.646 24.05%
and 95.76 6 11.35% respectively; p 5 0.005, Figure 1) and similar to
that with fludarabine (42.84 6 11.03%). A reduction in metabolic
activity with 10 mM Tnv-6 was evident even at 8 hours of incubation
(84.16 6 9.9% of controls, p 5 0.007), similar to the effects of
fludarabine (83.96 6 6.82%) and therefore, further characterization
of the cellular response to Tnv-6 was undertaken predominantly in 8
hour cultures.
Tnv-6 does not affect normal hematopoiesis. In contrast to the
effects of Tnv-6 on CLL cells, the proportion of HPC recovered
following 8 hours of culture with 10 mM Tnv-6 (102 6 38.8 per 2
3 105 cultured MNC, n 5 4) was similar to that in control cultures
(99.126 39.5, n5 4, p5 0.5) (Figure 2). Thus, the dose and duration
of exposure to Tnv-6 that induces cytotoxicity in CLL cells does not
cause hematopoietic toxicity in vitro. In contrast, the HPC yield from
cultures containing fludarabine was significantly lower (75.3 6
26.11, n 5 4) than in control (p 5 0.017) or Tenovin-6 containing
cultures (p 5 0.021).
In mice treated with Tnv-6, no differences in the cellularity of
blood, marrow or spleen were observed after 7 and 19 days of
treatment compared to control animals, indicating the absence of
short-term hematopoietic toxicity with Tnv-626.
Tnv-6 does not induce p53 or apoptosis in CLL. Intracellular
proteins reportedly altered by Tnv-6 treatment in malignant cell
lines23 were investigated in cultured CLL cells (Figure 3 and
Supplementary Figure 2). As expected, levels of phosphorylated
c-H2AX were unchanged following exposure to Tnv-6 (0.86 6
0.17-fold over levels in controls; p 5 0.6), confirming the drug’s
non-genotoxic properties24,25. Unexpectedly however, no consistent
increase in total p53 was detected, with the heterogeneity in
expression resulting in no significant overall change (1.5 6 0.37-
fold, p 5 0.37) over controls. In contrast, induction of p53 was
evident in all specimens cultured with fludarabine (3.8 6 1.7-fold;
p5 0.007). No consistent up-regulation of p21/waf1 or acetylation of
Figure 1 | Dose-dependent cytotoxicity of Tnv-6. Compared to 5 mM or
1 mM, greater cytotoxicity to CLL cells was evident with 10 mMof Tnv-6 at
24 hours (n 5 10, p 5 0.005, Student’s t-test on paired samples), and at
equivalent levels to 3 mM fludarabine (a). Cytotoxicity with 10 mM Tnv-6
at 8 hours (relative to controls, p 5 0.007,) was also similar to fludarabine-
containing cultures (p 5 non-significant) (b).
www.nature.com/scientificreports
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p53 and tubulin was evident, with variable increases in acetylated
Histone-H4 (2.0 6 0.57-fold; p 5 0.075). These expression profiles
were consistent in repeat cultures with Tnv-6. To exclude the
possibility that longer periods of drug-exposure could alter protein
expression, CLL cells were cultured with Tnv-6 (at doses of 1, 5 or
10 mM) for 24 hours. However, protein-expression remained
unchanged in these extended cultures, and with the use of freshly
isolated cells in culture. Interpretation of results from 24 hour
cultures with 10 mM Tnv-6 was confounded by variable cell
recovery and inconsistent expression of b-actin.
When cells were examined for changes in proteins associated with
apoptotic signaling, cleaved PARP-1 and caspase-3 were not detected
in any specimen either at 8 or and 24 hours, unlike in fludarabine-
treated cultures (Figure 4).
Tnv-6 induces a distinct transcriptomic profile in CLL. To identify
the mechanisms by which Tnv-6 acts and the comparison with the
action of a broad spectrum HDAC inhibitor, we performed global
gene expression profiling of cells (n 5 5) treated with Tnv-6 or TSA
as single agents, or with the two HDAC inhibitors simultaneously.
Normalization and expression values for arrays were calculated using
both dCHIP and RMA with the Affy packages available from
Bioconductor31,32. Similar results were obtained using dCHIP or
RMA, helping to confirm the validity of the expression data
obtained. Results are presented only for dCHIP data. After filtering
gene sets to remove those that are not expressed, unsupervised
hierarchical clustering of the remaining 18,421 gene probe sets
identified two distinct clusters of samples, the first representing
control samples and cells treated with Tnv-6 and the second
cluster consisting of cells treated with either TSA alone or with
combination therapy (Tnv-6 and TSA) [Supplementary Figure
Figure 3 | Expression levels of select Sirtuin substrates following
treatment with Tnv-6. Levels of p53, acetylated histone H4 (ac-H4), and
acetylated tubulin (acet-tubulin) from 8 hour cultures of CLL cells with
Tnv-6 were quantified using densitometry, standardized to respective
b-actin values and expressed as the fold-change over untreated (control)
cultures. In addition, phosphorylated H2AX (p-H2AX) levels were also
quantified. Although heterogeneity of p53 and acet-H4 expression existed
between patients, no significant difference in levels of any of the proteins
was evident in Tnv-6-treated cells (Student’s t-test on paired samples).
Figure 4 | Pro-apoptotic protein marker expression following Tnv-6
treatment. Representative Western blot gel images reveal the absence of
cleaved caspase-3 (a) and PARP-1 (b) in CLL cells cultured with Tnv-6
(Tnv-6), similar to untreated cultures (Control). In contrast, cleaved forms
of both proteins were detected in CLL cells cultured with fludarabine (1).
Figure 2 | Human hematopoietic progenitor cell development (HPC)
with Tnv-6. Numbers of HPC recovered after 8 hours of culture of normal
peripheral blood mononuclear cells with control medium (Control), Tnv-
6 (10 mM) or fludarabine (3 mM). The recovery of HPC fromControls and
cultures incubated with Tnv-6 was equivalent (p5 0.5), but higher than in
fludarabine-containing cultures (p , 0.05, Student’s t-test on paired
samples), suggesting that the anti-leukemic dose of Tnv-6 is non-toxic to
human HPC in vitro.
www.nature.com/scientificreports
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3(a)]. In the first cluster there is a clear distinction between the
expression profiles of the control samples and those following
Tnv-6 treatment, allowing the identification of genes altered by
Tnv-6 treatment. Within the second cluster, each of the five
patients forms a unique sub-branch, in which the combined
treatment consistently leads to an overall gene expression profile
that is closer to the Tnv-6 cluster. The clustering pattern also
indicates that TSA has an overall larger effect on gene expression
changes than Tnv-6 [Supplementary Figure 3(b)], in keeping with
the broader spectrum of HDAC inhibition by TSA.
Using a criteria of at least 1.5-fold differently expressed (at 90%
confidence) and an absolute difference of at least 100 between com-
parisons with Benjamini and Hochberg false-discovery correction
for multiple testing (P , 0.05), 450 probe sets were identified as
differentially expressed between Tnv-6-treated and control cultures
(Supplementary Table 1A). Using the available Gene Ontology
annotations, differentially expressed genes included those regulating
immune responses and cellular steroid and lipid metabolism. In
particular, significant overrepresentation of genes involved in cho-
lesterol biosynthesis was observed (p 5 0.000037). Consistent with
the lack of p53 protein expression in Tnv-6-treated cells, genes
associated with p53 activation were not altered (barring a 2.7-fold
up-regulation of CDKN1A, p 5 0.028), with no evidence for the
induction of growth arrest or apoptotic pathways. Notably, the activ-
ity of genes regulating autophagy-lysosomal pathways36 was signifi-
cantly altered in the presence of Tnv-6 (Table 1).
In comparison with Tnv-6, twice as many gene probe sets (944)
were identified in TSA-treated cells compared to control cells
(Supplementary Table 1B). Cells treated with TSA differentially
expressed genes involved in amino acid metabolism and cell-cycle
regulation. In combination, Tnv-6 and TSA affected the expression
levels of 1364 gene probe sets compared to control cells
(Supplementary Table 1C), including gene products regulating bio-
logical processes affected individually by the two agents, and addi-
tionally, cytoskeletal and organelle proteins. Cholesterol biosynthesis
was again the dominant intracellular signaling pathway affected by
combined HDAC inhibition.
To validate the data, changes in the activity of select genes import-
ant for cholesterol biosynthesis were measured in Tnv-6-treated cells
(n 5 5) using real-time PCR. Consistent with the expression array
results, significant increases in activity of 3-hydroxy-3-methyl-glu-
taryl-CoA reductase (HMGCR), Lanosterol synthase (LSS) and the
transcriptional regulator Sterol Regulatory Element-Binding Protein-
2 (SREBP-2) were detected in CLL cells cultured for 8 hours with
Tnv-6 (Supplementary Figure 4). By gas chromatography-mass spec-
trometry, the mean cholesterol content (per 106 cells) was 1.8-fold
higher in cells exposed to Tnv-6 for 24 hours than in controls (p 5
NS; data not shown).
Tnv-6 increases autophagosomes in CLL cells. Since autophagy-
lysosomal dysregulation was evident in gene expression profiles of
Tnv-6-treated CLL cells, we studied the ultrastructure of cultured
cells from 3 available specimens with using transmission electron-
microscopy (TEM), to clarify mechanisms of Tnv-6-induced
cytotoxicity.
By TEM, no changes in chromatin, cytosolic or membrane struc-
ture to indicate apoptosis37 were evident in any of the 3 specimens at
8 or 24 hours following Tnv-6 treatment (Figure 5). In particular,
there was no chromatin or cytoplasmic condensation, and nuclear
fragmentation and apoptotic bodies were absent. Instead, cells from
cultures with Tnv-6 had an increase in double-membrane bound
vacuoles within the cytoplasm (Figure 5). These vacuoles contained
cellular debris and recognizable cytoplasmic organelles, suggesting
they are autophagic in nature38,39.We counted these autophagosomal
structures in a total of 100 cell-sections from cultures treated with
Tnv-6 for 8 hours and controls, and expressed the results as the
average number of autophagosomes per cell. A mean 5-fold increase
(range 4–6) in numbers of autophagosomes per cell was evident in
the presence of Tnv-6 over corresponding controls (Figure 5; n5 3; p
5 0.04), suggesting altered cellular autophagy38,39 following Tnv-6-
treatment.
Tnv-6 consistently dysregulates autophagy in CLL. To confirm
changes in autophagy in Tnv-6-treated cells, we quantified changes
in the key autophagy-pathway cytosolic protein LC3 by Western
blotting (n 5 10)39,40. LC3 is small cytosolic ubiquitin-like molecule
that is recruited to autophagosomes upon autophagy induction. Here,
it is conjugated to lipid, phosphatidylethanolamine, which can readily
be visualized by increased mobility in SDS-PAGE and Western
blotting. Therefore, an increase in conversion of LC3 (form I) to its
lipidated form (LC3-II) occurs during autophagy. We consistently
found that Tnv-6 lead to an increase in LC3-II levels (4.31 6 1.1-
fold over controls; p 5 0.01) [Figure 6 (a)].
Autophagy is a dynamic process that protects cells under metabolic
stress conditions, with the early stage formation of autophagosomes
being balanced by their degradation upon delivery to lysosomes40.
Therefore, an increase in autophagosomes and LC3 lipidation,
though consistent with autophagy stimulation, could also result from
a block in the late stages of autophagy, for example, fusion of autop-
hagosomes with lysosomes39. To distinguish between these two pos-
sibilities, lysosomal degradation was blocked by treating cultures with
10 nm bafilomycin-A1 (that targets vacuolar-type H1-ATPase), such
that stimulation of autophagy following Tnv-6 treatment would result
in a synergistic accumulation of LC3-II By analysis of LC3-II bands in
Western blot images [Figure 6 (b)] using densitometry, an increased
LC3-II expression was evident with bafilomycin-A compared to
untreated cells (p 5 0.03, n 5 3), similar to the increase in Tnv-6-
treated cells. Addition of bafilomycin-A1 to Tnv-6 cultures caused no
further increase in LC3-II compared to Tnv-6 only treated samples (p
5 0.15). This was in contrast to combining bafilomycin-A1 with
4 mM Ku-006379441 (known to stimulate autophagy through direct
inhibition of the mTOR pathway) in two cultures [Figure 6(c) and
Supplementary Figure 5]. These results demonstrate that Tnv-6 does
not stimulate autophagy and identify a role for Tnv-6 in the inhibi-
tion of the late stages of autophagy.
Table 1 | Fold-change in autophagy-lysosomal pathway gene
activity in transcriptomic profiles of CLL cells following Tnv-6-treat-
ment (n 5 5). Negative values reflect down-regulation of gene
expression
Gene fold change p value
aryl hydrocarbon receptor nuclear translocator 1.58 0.038
calnexin 1.58 ,0.001
calpain 10 1.44 0.032
chromatin modifying protein 2B 1.76 0.001
cyclin-dependent kinase inhibitor 1A (p21, Cip1) 2.7 0.028
cystatin B (stefin B) 3.17 0.008
cystinosis, nephropathic 2.15 0.004
DnaJ (Hsp40) homolog, subfamily B, member 9 1.55 0.018
Fas (TNFRSF6)-associated via death domain 21.63 0.033
galactosamine (N-acetyl)-6-sulfate sulfatase 21.52 0.044
hexosaminidase A (alpha polypeptide) 2.08 0.017
inositol hexaphosphate kinase 1 1.48 0.027
lysosomal-associated membrane protein 1 2.54 ,0.001
lysosomal-associated membrane protein 2 1.8 0.027
Niemann-Pick disease, type C2 2.25 0.017
optineurin 2.61 0.003
phosphoinositide-3-kinase, class 3 1.17 0.0248
unc-51-like kinase 3 (C. elegans) 1.53 ,0.001
upstream transcription factor 2, c-fos interacting 1.73 0.011
vacuolar protein sorting 41 (yeast) 1.34 0.042
www.nature.com/scientificreports
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Figure 5 | Ultrastructural changes following culture with Tnv-6. Representative TEM images of cells from one (out of 3) CLL specimen after culture
without (a) or in the presence of Tnv-6 (b) demonstrate differences in cellular ultrastructure and integrity after Tnv-6 treatment. To visualize subcellular
differences in greater detail, images at highermagnification are shown of a cell each from control cultures (c) and Tnv-6 containing cultures (d). The latter
cell, highlighted within an interrupted line box in (b) contains double-membrane bound cytoplasmic vacuoles (black arrows) suggestive of early
autophagosomes. In addition, larger vacuoles containing morphologically intact material and partially degraded organelles (white arrow) suggestive of
late autophagosomes are also seen. Numbers of autophagosomes per cell in 100 cell-sections per culture (n 5 3) were 5-fold higher (p 5 0.04) in Tnv-6-
treated cultures than in corresponding controls (e).
www.nature.com/scientificreports
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In support of these data, Tnv-6 treatment resulted in a 1.5-fold
increase (range 1.3–1.8) in levels of another autophagy-associated
protein p62/SQSTM1 over control cells [n 5 3, p 5 0.045;
Figure 6(d)]. p62 is an LC3 adaptor protein that is degraded by
autophagy40,42, hence an increase in autophagic flux should result
in reduced p62 levels43. As the opposite in seen with Tnv-6, this
indicates, along with the increased number of autophagosomes seen
by TEM and the block in LC3-II flux, that Tnv-6 inhibits autopha-
gosomal turnover in CLL cells to prevent the protective effect of
autophagic recycling of cytoplasmic contents.
Discussion
Our studies have identified that in CLL cells, the cytotoxic effects of
Tnv-6 may occur through the dysregulation of autophagy rather
than induction of apoptosis. Since no ‘hot-spot’ mutations in the
DNA-binding domain of TP53 were detected in cells from any
patient and p53-pathway responses to fludarabine were preserved,
we were expecting Tnv-6 to increase expression of p53-dependent
proteins, with resulting apoptosis15,24–26. However, no consistent
increase in p53 or p53-dependent transcriptional activity was
observed following Tnv-6 treatment, and no changes in caspase-3
and PARP-1 proteins, known to regulate apoptosis via p53-depend-
ent or independent mechanisms44,45 were detected. Furthermore,
TEM, considered the gold standard for detecting apoptosis37 demon-
strated the absence of quintessential ultrastructural apoptotic fea-
tures, even in cells cultured for extended periods with Tnv-6. In
contrast, increased autophagic vacuoles were identified in Tnv-6
treated cells. Corresponding increases in lipidated LC3 and p62/
sequestosome, together with changes in autophagy-lysosome path-
way gene activity provide strong evidence for an altered autophagic-
flux in CLL cells cultured with Tnv-6 that occurs in the absence of
significant p53 expression. Further evidence for the p53-independent
dysregulation of autophagy by Tnv-6 comes from the 2-fold increase
in LC3 expression-intensity observed in cells from a patient with
del(17p) CLL (commonly associated with mutant TP535) following
culture with Tnv-6 (Supplementary Figure 6), but these results
require confirmation in larger studies.
A role for Tnv-6 in inhibiting autophagy is suggested by the
increase in p62/sequestosome41 and supported by the absence of
synergistic accumulation of lipidated LC3 in cells cultured with
Tnv-6 and bafilomycin-A143. Since autophagy is a pro-survival cel-
lular strategy to maintain homeostasis40, inhibiting the protective
effect of autophagic recycling of cytoplasmic contents can lead to cell
death in CLL cells. The up-regulation of cholesterol synthesis genes
in Tnv-6-treated cells could reflect a compensatory response to a
block in LDL/cholesterol trafficking within the endocytic system,
lysosomal dysfunction and changes in autophagy36.
Tnv-69s ability to dysregulate autophagy in the absence of p53 up-
regulation in CLL cells contrasts with the p53-dependent apoptosis
reported in other neoplastic cells24–27 and could reflect biological
differences between different cell-types. In contrast to the tumor cells
examined previously24–27, most CLL cells are quiescent and metabo-
lically inactive in culture. Whether the cellular response to Tnv-6 is
influenced by cell-cycle status or cellular metabolic activity therefore
requires investigation. Alternatively, the preferential dysregulation
of autophagy in CLLmay arise from differences in the relative inhibi-
tion of SirT1 and SirT2 by Tnv-623,28 compared to other cells. Many
studies have firmly established the ability of Tnv-6 to inhibit
Sirtuins24–27,46,47 and the altered activity of Sirtuin-dependent genes
regulating metabolism48 seen here in the transcriptome of cells cul-
tured with Tnv-6 does suggest inhibition of SirT1/SirT2 activity in
CLL cells. Furthermore, the Tnv-6 effects would be consistent with
its Sirtuin inhibitory properties since a role for SirT1 in promoting
autophagy independent of p53 acetylation and activation during the
cellular survival response to starvation is recognized20. However, the
precise potency of Sirtuin inhibitors (including Tnv-6) against SirT1
and SirT2 remains difficult to interpret, making cellular responses
dependent on the cell-type or Sirtuin antagonist under investigation.
This context-dependent biological behavior could account for the
differences in results between studies15,16,20,24–27. Correlating levels
of SirT1 expression with Tnv-6 cytotoxicity could enable comment
on whether Tnv-69s effects could be mediated through SirT1 inhibi-
tion, but the presence of multiple protein bands in some patients and
the semi-quantitative nature of densitometry-based measurements is
likely to confound an accurate assessment of SirT1 levels in CLL
cells. In addition, the expression levels of SirT1 may not be a true
reflection of functional activity within cells, since its function can be
influenced by post-translational modifications, subcellular local-
ization and interactions with other proteins49. Experimental manip-
ulation of cellular SirT1 and/or SirT2 levels in cells towards
Figure 6 | Autophagy protein expression profiles following Tnv-6 treatment. Compared to untreated (Control) cultures, Tnv-6-containing CLL cell
cultures had increased lipidated LC3 (LC3-II, indicated by the lower band and arrow) (a). While a similar change in LC3-II was present in cells treated
with bafilomycin-A (Baf-A), a synergistic increase in LC3-II was absent when Tnv-6 was combined with bafilomycin-A1 (b), in contrast to cultures with
Ku-0063794 and bafilomycin-A1 (c). These data indicating a role for Tnv-6 as an autophagy-inhibitor are supported by the increase in cargo adaptor p62/
Sequestosome following Tnv-6 treatment (d).
www.nature.com/scientificreports
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phenocopying or antagonizing the effects of Tnv-6 would be an
attractive way to directly determine whether relative changes in
SirT content can alter the cellular response to Tnv-6, but the bio-
logical characteristics of primary human CLL cells make these stud-
ies technically challenging.
While the precise signaling involved in the cytotoxicity of Tnv-6 to
CLL cells remains to be elucidated, our studies demonstrate clearly
that Tnv-6, previously thought to mainly mediate p53-mediated
apoptotic responses, can be cytotoxic to CLL cells through a novel
mechanism, dysregulated autophagy.We further show that this com-
pound acts to inhibit autophagic-flux rather than initiate the autop-
hagic process, highlighting the importance of autophagy to stress
responses in CLL and the potential therapeutic utility of targeted
manipulation of autophagic-flux in CLL50,51.
Methods
Cell separation and processing.All studies were performed following approval from
Tayside Committee on Medical Research Ethics and Tayside Tissue Bank and all
patents gave informed consent for the use of their tissue for this study. Blood (20 ml)
was taken from 10 patients (median age 67 years, range 57–78) with CLL and a total
white cell count . 50 3 109/l (normal range 4–11), not currently on any treatment.
Three patients with stable disease were treatment-naive, 3 previously untreated
patients had progressive disease and 4 with stable disease had completed therapy at
least 12months prior to the date of blood sampling. Enriched populations of CLL cells
were isolated by density gradient centrifugation (Ficoll-PaqueTM Plus, 1.077, GE
Healthcare Bio-Sciences AS, Uppsala). The enrichment for neoplastic cells (. 92%)
was confirmed by the co-expression of CD5 and CD19 by flow-cytometry
(FACSscan). Genomic DNAwas extracted fromCLL cells using the Qiagen BioRobot
EZ1 (Qiagen) using protocols (EZ1 DNA Blood Card) recommended by the
manufacturer (Qiagen). Samples were quantified by spectrophotomeric reading using
the NanoDropH ND-1000 (NanoDrop Technologies) and stored at 280uC. In
addition, cells were cyropreserved in dimethylsulphoxide (Sigma, Steinheim,
Germany) in Tayside Tissue Bank for use in cell culture studies. Previous studies1,29
have suggested the concordance of gene and protein expression in fresh and
cryopreserved CLL cells from individual patients, nevertheless, we validated
important observations in freshly isolated CLL cells.
TP53 sequence analysis. Exons 5–9 of the TP53 gene (the mutation hotspot region
coding for the DNA binding pf p53) were amplified by PCR using genomic DNA
extracted from freshly isolated cells. The purified products were directly sequenced
using the ABI PRISMH BigDyeTM Terminators V 3.0 sequencing kit and run on an
ABI 3130 genetic analyzer (Applied Biosystems).
Cell culture. Cryopreserved CLL cells were thawed and washed. Trypan Blue
exclusion assays indicated that. 99% of cells were viable prior to culture. Cells were
cultured at a final concentration of 2 3 106 cells/ml in medium (RPMI, Sigma)
containing 10% fetal calf serum (Harlan sera-Lab Ltd, Loughborough, UK) at 37uC.
Cultured CLL cells were incubated with either 1, 5 or 10 mM Tnv-6, 9-m-D-
arabinosyl-2-fluoroadenine (fludarabine) monophosphate (final concentration of
3 mM, Sigma), or Trichostatin-A (TSA) (Sigma, 40 nM) that inhibits Class I, II and IV
HDAC. The synthesis of Tnv-6 including full analytical characterization has been
described recently23. Cultures containing fludarabine served as ‘positive’ controls to
compare the effects of Tnv-6. ‘Negative’ controls consisted of cultures containing an
appropriate volume of drug diluent.
Cytotoxicity assay. The CellTiter 96 Aqueous One Solution Assay (Promega) was
used to screen for the effects of Tnv-6 on CLL cells. The results enabled identification
of incubation times and Tnv-6 doses for a detailed characterization of the biological
responses to Tnv-6.
Expression of intracellular proteins. Intracellular protein expression following Tnv-
6 treatment was studied byWestern blot analysis of cultured CLL cell lysates. In brief,
cells were lysed on ice using buffer containing 1%Tergitol-type NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, protease and phosphatase inhibitors, and snap-frozen and
thawed three times. Following centrifugation at 14,000 rpm for 10 minutes at 4uC,
protein concentration was determined by Pierce Bicinchoninic Acid (BCA) assay and
samples stored at 280uC. Equal amounts of proteins for each sample were migrated
in 10% SDS-PAGE, blotted onto nitrocellulose filters, blocked with a 10% suspension
of dried skimmed milk in PBS, and incubated with antibodies to SirT1 (151000,
Upstate 07-131), total p53, (DO1, 15100) and p21/waf1 (clone 118, 151000), kindly
gifted by Dr B Vojtesek, Masaryk Memorial Cancer Institute, Brno, Czech Republic),
acetylated p53 (Ac-p53 K373-382, Upstate15250), acetylated Histone H4 (Sigma,
15200), acetylated tubulin (Sigma, 151000), cleaved caspase-3 (Cell Signaling,
151000), cleaved poly (ADP-ribose) polymerase (PARP-1 Santa Cruz,15500),
phosphorylated c-H2AX (Cell Signaling, 15500), microtubule-associated protein 1
light chain 3 (LC3, Sigma, 151000) and p62/sequestosome (Abnova, 151000).
As a control for protein loading, the lower part of each membrane was re-probed
with a mouse monoclonal antibody to b-actin (AC-74; Sigma). Immunoreactive
bands for proteins of interest were quantified by densitometry in a linear range using
calibrated office scanner and ImageJ software, and the ratio of the immunoreactive
protein bands and b-actin was calculated. Protein levels from cells cultured with Tnv-
6 were expressed as the fold-change over control cultures on the same membrane.
Global gene expression profiling. Given the relatively restricted effects of Tnv-6
against HDAC24,25, we investigated whether Tnv-6-treatment altered a different gene
program in CLL cells, compared to a more broad-spectrum HDAC inhibitor such as
TSA. Global gene expression profiling of cells treated with Tnv-6 or TSA as single
agents, or treated with the two HDAC inhibitors simultaneously was therefore
performed. In brief, RNA was extracted from cells following culture with Tnv-6, TSA
or a combination of the two agents, and control cultures using the RNeasyHMini Kit
(Qiagen). After reverse transcription, synthesis of biotinylated cRNA and
fragmentation of labeled cRNA, probes were hybridized to Affymetrix GeneChipH
Human U133 Genome 2.0 arrays (BioScience, Nottingham, UK) at the MRC
geneservice (Cambridge, United Kingdom), capable of analyzing the relative
expression level of greater than 47,000 transcripts and variants, including more than
38,500 well-characterized genes and UniGenes. All specimens passed standard RNA
quality and cDNA/cRNA efficiency tests before being hybridized and all arrays passed
the recommended quality control assessments performed in BioConductor and
Dchip30–32. Percentages of probe sets where the mean signal of the mismatch probes
(MM) was greater than the corresponding perfect match (PM) were calculated along
with RNA degradation plots using AffyRNAdeg. Images of all Chips were inspected
for defects. We also used the in-built outlier detection methods in dCHIP together
with percentage present calls, analysis of box-plots and histograms and the RNAdeg
packages available on BioConductor as recommended for quality control prior to
analysis of data. All arrays performed above the recommendations.
Raw data on global gene expression profiles were uploaded in dCHIP (version
3.7.0) for normalization and supervised and unsupervised analysis30. Genes were
filtered to remove probes that are not changed across conditions (coefficient of
variation 0.2, SE/mean, 1,000), and to include only those probe sets that are called
‘‘present’’ in at least one condition, have low variation between replicates [0,median
(SD/mean), 0.5], and have an expression value. 50 in at least one set of replicate
samples. Genes were selected at significance (P , 0.05 with false discovery rate
correction) and a mean fold-difference (at least 1.5-fold at 90% confidence) between
the 2 groups for Bayesian classification. Supervised analysis was used to identify genes
and pathways/signatures associated with specific drug treatments. MIAME-compli-
ant microarray data will be deposited in NCBI’s Gene Expression Omnibus.
Electron microscopy. Sub-cellular changes in CLL cells following exposure to Tnv-6
were studied by fixing cultured cells in 4% PFA, 2.5% gluteraldehyde in 0.2 M PIPES.
Cells were post-fixed in 1% osmium tetroxide, washed in dH2O, dehydrated through
graded ethanols into propylene oxide and then infiltrated with Durcupan resin
through propylene oxide/Durcupan steps. Tissue in Durcupan was then placed in
moulds and baked at 60uC overnight. Thin sections (Leica Ultramicrotome) were
stained with uranyl acetate and lead citrate33, semi-thin and ultra-thin sections were
stained with Richardson’s stain (1% toluidine blue and 1% methylene blue in 1%
borax) and viewed on a TECNAI 12 (FEI) transmission electron microscope.
Effects of Tnv-6 on human hematopoietic progenitor development in vitro. The
potential hematopoietic toxicity of Tnv-6 was studied in suspension cultures of
human hematopoietic progenitor cells (HPC). Briefly, 2 3 106 blood cryopreserved
MNC fromhealthy volunteers were washed and incubated in 10% fetal calf serum and
Iscove’s Modified Dulbecco’s Medium at 37uC with or without Tnv-6 or fludarabine.
Following culture, cells were recovered and washed. A total of 2 3 105 cells were
assayed for erythroid (BFU-E) and myeloid (CFU-GM) HPC in semi-solid
clonogenic medium (STEMCELL Technologies, Vancouver, Canada), in accordance
to the manufacturer’s instructions. The sum total of BFU-E and CFU-GM in 2 3 105
cultured MNC was used to measure changes in HPC following exposure to Tnv-6 or
fludarabine.
Effects of Tenovin-6 on murine hematopoiesis. Tnv-6 at a dose of 50 mg/kg was
administered by intraperitoneal injection to female SCIDmice (Harlan) in a schedule
shown to delay growth of tumour cells in xenograft models24. This dosing schedule
was equivalent to an in vitro dose of 8.9 mM. The animals were sacrificed at 7 and 19
days. Cell numbers in blood, bone marrow and spleen were assessed morphologically
after staining with Hematoxylin and Eosin and compared with control animals not
exposed to Tnv-6.
Statistical analysis.The arithmetic meanwas used tomeasure the central tendency of
data and the dispersion of values around the mean was expressed as the standard
deviation (s.d.) in analysis of raw data, i.e. mean 6 s.d. The significance of difference
between mean values was determined using Student’s t-test (paired). All p-values
were two-tailed and statistical-significance was set at the level of p , 0.05.
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